In a significant development for the pharmaceutical industry, Pacira Pharmaceuticals Inc.’s patent on a nonopioid painkiller has been declared invalid by a federal judge in New Jersey. The ruling paves the way for generic versions of Exparel, a long-acting injectable designed to manage postsurgical pain. The decision marks a notable win for the manufacturers of generic drugs, potentially altering the market dynamics for postsurgical pain management.
For further details, you can read more about the ruling on Law360.